Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almac Clinical Technologies has signed $12 million worth of new studies within the past several weeks, including one of the largest studies in the company's history.
Subscribe to our email newsletter
This new global mega-study will involve close to 20,000 patients and requires provision of very sophisticated technological and statistical solutions, a key strength of Almac service offering. The firm has recently signed a record number of new bookings, including a mix of large global studies.
Jim Murphy, president of Almac Clinical Technologies, said: “We are seeing an increase in the number of large, global, complex trials as well as smaller adaptive clinical trials, each requiring sophisticated randomization and drug management approaches. Sponsors seem to be turning to experienced global firms, such as Almac, with strong project management expertise and technologies to make those trials successful.”